|
1
|
Barta JA, Powell CA and Wisnivesky JP:
Global epidemiology of lung cancer. Ann Glob Health.
85(85)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
World Health Organization: Cancer Today.
2021. Accessed from https://gco.iarc.fr/today/home.
|
|
3
|
Blandin Knight S, Crosbie PA, Balata H,
Chudziak J, Hussell T and Dive C: Progress and prospects of early
detection in lung cancer. Open Biol. 7(7)2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zhou K, Zhao S, Guo W and Ding L: Efficacy
and safety of erlotinib combined with bevacizumab in the treatment
of non-small cell lung cancer: A systematic review and
meta-analysis. Medicine (Baltimore). 99(e18771)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Atal S, Asokan P and Jhaj R: Recent
advances in targeted small-molecule inhibitor therapy for
non-small-cell lung cancer-An update. J Clin Pharm Ther.
45:580–584. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zugazagoitia J, Guedes C, Ponce S, Ferrer
I, Molina-Pinelo S and Paz-Ares L: Current challenges in cancer
treatment. Clin Ther. 38:1551–1566. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Liao YH, Li CI, Lin CC, Lin JG, Chiang JH
and Li TC: Traditional Chinese medicine as adjunctive therapy
improves the long-term survival of lung cancer patients. J Cancer
Res Clin Oncol. 143:2425–2435. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wang Y, Liu Y, Du X, Ma H and Yao J: The
anti-cancer mechanisms of berberine: A Review. Cancer Manag Res.
12:695–702. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Guo Q, Li J and Lin H: Effect and
molecular mechanisms of traditional Chinese medicine on regulating
tumor immunosuppressive microenvironment. BioMed Res Int.
2015(261620)2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lin YY, Lee IY, Huang WS, Lin YS, Kuan FC,
Shu LH, Cheng YC, Yang YH and Wu CY: Danshen improves survival of
patients with colon cancer and dihydroisotanshinone I inhibit the
proliferation of colon cancer cells via apoptosis and skp2
signaling pathway. J Ethnopharmacol. 209:305–316. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lin YS, Shen YC, Wu CY, Tsai YY, Yang YH,
Lin YY, Kuan FC, Lu CN, Chang GH, Tsai MS, et al: Danshen Improves
Survival of Patients With Breast Cancer and Dihydroisotanshinone I
Induces Ferroptosis and Apoptosis of Breast Cancer Cells. Front
Pharmacol. 10(1226)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Su CY, Ming QL, Rahman K, Han T and Qin
LP: Salvia miltiorrhiza: Traditional medicinal uses,
chemistry, and pharmacology. Chin J Nat Med. 13:163–182.
2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Tung YT, Chen HL, Lee CY, Chou YC, Lee PY,
Tsai HC, Lin YL and Chen CM: Active component of Danshen (Salvia
miltiorrhiza Bunge), tanshinone I, attenuates lung
tumorigenesis via inhibitions of VEGF, Cyclin A, and Cyclin B
expressions. Evid Based Complement Alternat Med.
2013(319247)2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
La Fontaine S and Mercer JF: Trafficking
of the copper-ATPases, ATP7A and ATP7B: Role in copper homeostasis.
Arch Biochem Biophys. 463:149–167. 2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Shanbhag V, Jasmer-McDonald K, Zhu S,
Martin AL, Gudekar N, Khan A, Ladomersky E, Singh K, Weisman GA and
Petris MJ: ATP7A delivers copper to the lysyl oxidase family of
enzymes and promotes tumorigenesis and metastasis. Proc Natl Acad
Sci USA. 116:6836–6841. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yang T, Chen M, Chen T and Thakur A:
Expression of the copper transporters hCtr1, ATP7A and ATP7B is
associated with the response to chemotherapy and survival time in
patients with resected non-small cell lung cancer. Oncol Lett.
10:2584–2590. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Li YQ, Chen J, Yin JY, Liu ZQ and Li XP:
Gene expression and single nucleotide polymorphism of ATP7B are
associated with platinum-based chemotherapy response in non-small
cell lung cancer patients. J Cancer. 9:3532–3539. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Samimi G, Safaei R, Katano K, Holzer AK,
Rochdi M, Tomioka M, Goodman M and Howell SB: Increased expression
of the copper efflux transporter ATP7A mediates resistance to
cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Clin Cancer Res. 10:4661–4669. 2004.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Li YQ, Zhang XY, Chen J, Yin JY and Li XP:
ATP7B rs9535826 is associated with gastrointestinal toxicity of
platinum-based chemotherapy in nonsmall cell lung cancer patients.
J Cancer Res Ther. 14:881–886. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Li YQ, Yin JY, Liu ZQ and Li XP: Copper
efflux transporters ATP7A and ATP7B: Novel biomarkers for platinum
drug resistance and targets for therapy. IUBMB Life. 70:183–191.
2018.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Lee CY, Sher HF, Chen HW, Liu CC, Chen CH,
Lin CS, Yang PC, Tsay HS and Chen JJ: Anticancer effects of
tanshinone I in human non-small cell lung cancer. Mol Cancer Ther.
7:3527–3538. 2008.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Huang W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Walter W, Sánchez-Cabo F and Ricote M:
GOplot: An R package for visually combining expression data with
functional analysis. Bioinformatics. 31:2912–2914. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43:D447–D452. 2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Doncheva NT, Morris JH, Gorodkin J and
Jensen LJ: Cytoscape StringApp: Network analysis and visualization
of proteomics data. J Proteome Res. 18:623–632. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ministry of Science and Technology of the
People's Republic of China: 2021. Accessed from: http://www.most.gov.cn/xxgk/xinxifenlei/fdzdgknr/fgzc/gfxwj/gfxwj2010before/201712/t20171222_137025.html.
|
|
28
|
Fu L, Han B, Zhou Y, Ren J, Cao W, Patel
G, Kai G and Zhang J: The anticancer properties of tanshinones and
the pharmacological effects of their active ingredients. Front
Pharmacol. 11(193)2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhou J, Jiang YY, Chen H, Wu YC and Zhang
L: Tanshinone I attenuates the malignant biological properties of
ovarian cancer by inducing apoptosis and autophagy via the
inactivation of PI3K/AKT/mTOR pathway. Cell Prolif.
53(e12739)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wang L, Wu J, Lu J, Ma R, Sun D and Tang
J: Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway
by tanshinone I in human breast cancer cell lines. Mol Med Rep.
11:931–939. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Adorno-Cruz V and Liu H: Regulation and
functions of integrin α2 in cell adhesion and disease. Genes Dis.
6:16–24. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ren D, Zhao J, Sun Y, Li D, Meng Z, Wang
B, Fan P, Liu Z, Jin X and Wu H: Overexpressed ITGA2 promotes
malignant tumor aggression by up-regulating PD-L1 expression
through the activation of the STAT3 signaling pathway. J Exp Clin
Cancer Res. 38(485)2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chuang YC, Wu HY, Lin YL, Tzou SC, Chuang
CH, Jian TY, Chen PR, Chang YC, Lin CH, Huang TH, et al: Blockade
of ITGA2 Induces Apoptosis and Inhibits Cell Migration in Gastric
Cancer. Biol Proced Online. 20(10)2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ding W, Fan XL, Xu X, Huang JZ, Xu SH,
Geng Q, Li R, Chen D and Yan GR: Epigenetic silencing of ITGA2 by
MiR-373 promotes cell migration in breast cancer. PLoS One.
10(e0135128)2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Van Scherpenzeel M, Timal S, Rymen D,
Hoischen A, Wuhrer M, Hipgrave-Ederveen A, Grunewald S, Peanne R,
Saada A, Edvardson S, et al: Diagnostic serum glycosylation profile
in patients with intellectual disability as a result of MAN1B1
deficiency. Brain. 137:1030–1038. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wang HF, Wu JH, Gai JW, Yang SQ, Ma QT, Ma
HS and Feng Q: MAN1B1 is associated with poor prognosis and
modulates proliferation and apoptosis in bladder cancer. Gene.
679:314–319. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Funa NS, Reddy K, Bhandarkar S, Kurenova
EV, Yang L, Cance WG, Welsh M and Arbiser JL: Shb gene knockdown
increases the susceptibility of SVR endothelial tumor cells to
apoptotic stimuli in vitro and in vivo. J Invest Dermatol.
128:710–716. 2008.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Funa NS, Kriz V, Zang G, Calounova G,
Akerblom B, Mares J, Larsson E, Sun Y, Betsholtz C and Welsh M:
Dysfunctional microvasculature as a consequence of shb gene
inactivation causes impaired tumor growth. Cancer Res.
69:2141–2148. 2009.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Thorlacius-Ussing J, Kehlet SN, Rønnow SR,
Karsdal MA and Willumsen N: Non-invasive profiling of
protease-specific elastin turnover in lung cancer: Biomarker
potential. J Cancer Res Clin Oncol. 145:383–392. 2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wright KD, Miller BS, El-Meanawy S, Tsaih
SW, Banerjee A, Geurts AM, Sheinin Y, Sun Y, Kalyanaraman B, Rui H,
et al: The p52 isoform of SHC1 is a key driver of breast cancer
initiation. Breast Cancer Res. 21(74)2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Xu X, Hu Y, Zhai X, Lin M, Chen Z, Tian X,
Zhang F, Gao D, Ma X, Lv L, et al: Salvianolic acid A
preconditioning confers protection against concanavalin A-induced
liver injury through SIRT1-mediated repression of p66shc in mice.
Toxicol Appl Pharmacol. 273:68–76. 2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Hou T, Tong C, Kazobinka G, Zhang W, Huang
X, Huang Y and Zhang Y: Expression of COL6A1 predicts prognosis in
cervical cancer patients. Am J Transl Res. 8:2838–2844.
2016.PubMed/NCBI
|
|
43
|
Owusu-Ansah KG, Song G, Chen R, Edoo MIA,
Li J, Chen B, Wu J, Zhou L, Xie H, Jiang D, et al: COL6A1 promotes
metastasis and predicts poor prognosis in patients with pancreatic
cancer. Int J Oncol. 55:391–404. 2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
You DJ, Park CR, Furlong M, Koo O, Lee C,
Ahn C, Seong JY and Hwang JI: Dimer of arfaptin 2 regulates NF-κB
signaling by interacting with IKKβ/NEMO and inhibiting IKKβ kinase
activity. Cell Signal. 27:2173–2181. 2015.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Verbeke H, Struyf S, Berghmans N, Van
Coillie E, Opdenakker G, Uyttenhove C, Van Snick J and Van Damme J:
Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit
melanoma growth and metastasis. Cancer Lett. 302:54–62.
2011.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Li J, Tang Z, Wang H, Wu W, Zhou F, Ke H,
Lu W, Zhang S, Zhang Y, Yang S, et al: CXCL6 promotes non-small
cell lung cancer cell survival and metastasis via down-regulation
of miR-515-5p. Biomed Pharmacother. 97:1182–1188. 2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Davidsson J, Puschmann A, Tedgård U,
Bryder D, Nilsson L and Cammenga J: SAMD9 and SAMD9L in inherited
predisposition to ataxia, pancytopenia, and myeloid malignancies.
Leukemia. 32:1106–1115. 2018.PubMed/NCBI View Article : Google Scholar
|
